-grover
liked
$Palantir (PLTR.US)$
PE 650 +-
This balloon can be blown up for a long time.
I tried to put it a few times last week, but it didn't succeed.
Directly switch to CALL, there's still money to be made.
#This stock is still very high risk, it's better to clear it out first.
PE 650 +-
This balloon can be blown up for a long time.
I tried to put it a few times last week, but it didn't succeed.
Directly switch to CALL, there's still money to be made.
#This stock is still very high risk, it's better to clear it out first.
Translated
![Picture](https://sgsnsimg.moomoo.com/sns_client_feed/104769032/20250218/1739890867335-random1316-104769032-android-compress.jpg/thumb?area=104&is_public=true)
![Picture](https://sgsnsimg.moomoo.com/sns_client_feed/104769032/20250218/1739890871295-random1527-104769032-android-org.png/thumb?area=104&is_public=true)
13
7
-grover
liked
$YieldMax MSTR Option Income Strategy ETF (MSTY.US)$
Got this from grok :
Comparing the returns from executing a weekly covered call strategy on MicroStrategy (MSTR) stock versus investing an equal amount in the YieldMax MSTR Option Income Strategy ETF (MSTY) involves several nuances:
Covered Call Strategy on MSTR:
Pros:
Customization: You control the strike prices, expiration dates, and can adjust your positions based on market movements.
Potential for...
Got this from grok :
Comparing the returns from executing a weekly covered call strategy on MicroStrategy (MSTR) stock versus investing an equal amount in the YieldMax MSTR Option Income Strategy ETF (MSTY) involves several nuances:
Covered Call Strategy on MSTR:
Pros:
Customization: You control the strike prices, expiration dates, and can adjust your positions based on market movements.
Potential for...
14
-grover
liked
$Veracyte (VCYT.US)$
The extensive validation of Veracyte's Decipher platform at ASCO GU 2025, supported by 17 abstracts and publication in Annals of Oncology, represents a significant strengthening of the company's market position in cancer diagnostics. The data demonstrates three important commercial advantages:
First, the Decipher Prostate test's ability to predict treatment response in the NRG Oncology/RTOG 0534 trial provides a clear clinical utility case for insura...
The extensive validation of Veracyte's Decipher platform at ASCO GU 2025, supported by 17 abstracts and publication in Annals of Oncology, represents a significant strengthening of the company's market position in cancer diagnostics. The data demonstrates three important commercial advantages:
First, the Decipher Prostate test's ability to predict treatment response in the NRG Oncology/RTOG 0534 trial provides a clear clinical utility case for insura...
5
-grover
liked
-grover
liked
-grover
liked
5